Fast facts
| Field | Record |
|---|---|
| Company | Theranos, blood-testing startup founded 2003 in California |
| Peak private valuation | Approximately $9 billion, reported mid-2010s |
| SEC action | Civil fraud charges settled March 2018: penalty, share relinquishment, 10-year officer and director bar |
| Criminal outcome | Convicted January 2022 on four counts: conspiracy and wire fraud against investors; acquitted on patient-related counts |
| Sentence | 11 years and 3 months, imposed November 2022; reported to prison May 2023 |
The rise
Holmes founded Theranos in 2003 after leaving Stanford, promising blood tests run on very small samples using proprietary devices. Over the following decade the company raised hundreds of millions of dollars from prominent investors, signed retail partnerships, and assembled a board stocked with public figures. At its peak, reporting put the private valuation around $9 billion, making Holmes, on paper, one of the wealthiest founders in the country. Very little of the underlying technology claim was ever independently validated, and the board was notably light on scientists with relevant expertise, two facts diligence could have surfaced at the time.
The unravelling
The Wall Street Journal's investigative reporting, beginning in October 2015, revealed that Theranos was performing most tests on conventional third-party analysers rather than its own devices, and raised accuracy concerns. Regulatory sanctions on the company's laboratory operations followed, partnerships collapsed, and investors wrote the company down. In March 2018 the SEC charged Holmes with what it described as an elaborate, years-long fraud; she settled without admitting or denying the allegations, paying a $500,000 penalty, returning shares, surrendering voting control and accepting a ten-year bar from serving as an officer or director of a public company. Three months later she was criminally indicted alongside the company's former president, Ramesh "Sunny" Balwani. Theranos itself dissolved in 2018.
Conviction and sentence
After a four-month trial, a federal jury in January 2022 found Holmes guilty on four counts, one of conspiracy and three of wire fraud, all relating to deceiving investors. She was acquitted on counts concerning patients, and the jury did not reach a verdict on three further investor counts. In November 2022 she was sentenced to 135 months, 11 years and three months, and she began serving the sentence in May 2023. She and Balwani, convicted separately on twelve counts, were also ordered to pay restitution of about $452 million. Appeals did not disturb the conviction. Note the precision the record allows and requires: convicted of defrauding investors, acquitted of defrauding patients. Our adverse media guide insists on exactly this rung-by-rung accuracy, even where the overall record is as adverse as one can be.
Reading it through the framework
Against the seven checks, the Holmes record fails at every level where most adverse founder stories fail at none: a regulatory action naming her personally, criminal charges naming her personally, and a conviction to the criminal standard. There is no corporate-versus-personal ambiguity to untangle, no control timeline that could relocate responsibility, since she was founder, CEO and controlling shareholder throughout the conduct period. This is the benchmark case for what a flag verdict means: not bad press, not a failed company, but findings against the person. Contrast it with the Adam Neumann profile, where a spectacular corporate failure produced no personal findings at all, and the value of keeping the two categories separate becomes obvious.
Flag. Criminal conviction on investor fraud counts, an SEC settlement with a decade-long officer and director bar, and court-ordered restitution. The public record establishes personal liability directly and no further inference is needed.